Various follow-up studies have reported that AAV9-mediated CRISPR/Cas9 delivery effectively restored dystrophin expression in DMD mouse models harboring deletions of exons 43, 44, 45, 51, or 52 [84,102,103,104]. Here, DMD is linked to Duchenne muscular dystrophy.